Clinical Trial Update: Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness for Patients With Systemic Sclerosis With Interstitial Lung Disease [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating pomalidomide (CC-4047) for systemic sclerosis with interstitial lung disease was terminated; results posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Interstitial Lung Disease
• Scleroderma
• Systemic Sclerosis

Drugs mentioned

• Pomalidomide (Pomalidomide)

Snippet

Sponsor: Celgene | Conditions: Scleroderma, Systemic, Sclerosis, Systemic | Phase 2 | Status: TERMINATED | Results posted: 2019-10-18